The Association of the Expression Level of Protein Tyrosine Phosphatase PRL-3 Protein with Liver Metastasis and Prognosis of Patients with Colorectal Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2004 May 11

PMID 15133662

Citations 41

Authors

Lirong Peng

Jinying Ning

Ling Meng

Chengchao Shou

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate PRL-3 protein expression in normal colorectal epithelia and colorectal cancers with monoclonal antibody (MAb) against PRL-3.

Methods: MAb against PRL-3 was prepared with the hybridoma technique, and its specificity was confirmed with ELISA and Western blotting assays. The expression of PRL-3 protein in normal colorectal epithelia and colorectal cancers was examined by immunohistochemistry assay. Logistic regression and survival analysis were performed to determine the clinical significance of PRL-3 expression.

Results: MAb 3B6 against PRL-3 was obtained and showed high specificity. PRL-3 protein was expressed in two of 28 (7.1%) normal colorectal epithelia, 21 of 88 (23.9%) primary colorectal cancers, 22 of 41 (53.7%) metastatic lymph nodes and eight of 12 (66.7%) liver metastases, respectively. The PRL-3 expression rates of metastases were significantly higher than those of primary colorectal cancers and normal colorectal epithelia (P < 0.05). PRL-3 expression was significantly associated with the liver metastasis of colorectal cancer (P = 0.004) and tended to shorten survival time (P = 0.0145).

Conclusions: This is the first study demonstrating that PRL-3 is a potential marker for liver metastasis of colorectal cancer and negatively influences the prognosis of colorectal cancer patients.

Citing Articles

The PACT Network: PRL, ARL, CNNM, and TRPM Proteins in Magnesium Transport and Disease.

Jolly J, Blackburn J Int J Mol Sci. 2025; 26(4).

PMID: 40003994 PMC: 11855589. DOI: 10.3390/ijms26041528.

PRL-3 and MMP9 Expression and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells From Patients With Colorectal Cancer: Potential Value in Clinical Practice.

Hong X, Liang Q, Chen M, Yang H, Huang J, Yi S Front Oncol. 2022; 12:878639.

PMID: 35574414 PMC: 9104807. DOI: 10.3389/fonc.2022.878639.

Functional interrogation and therapeutic targeting of protein tyrosine phosphatases.

Krabill A, Zhang Z Biochem Soc Trans. 2021; 49(4):1723-1734.

PMID: 34431504 PMC: 8527391. DOI: 10.1042/BST20201308.

lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway.

Luo T, Gao Y, Zhangyuan G, Xu X, Xue C, Jin L Cancer Manag Res. 2020; 12:5395-5408.

PMID: 32753957 PMC: 7352448. DOI: 10.2147/CMAR.S249657.

Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations.

Zhang M, Wei Y, Liu Y, Guan W, Zhang X, Kong J iScience. 2019; 23(1):100766.

PMID: 31887658 PMC: 6941878. DOI: 10.1016/j.isci.2019.100766.

References

Matter W, Estridge T, Zhang C, Belagaje R, Stancato L, DIXON J . Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun. 2001; 283(5):1061-8. DOI: 10.1006/bbrc.2001.4881. View

Su J, Muranjan M, Sap J . Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr Biol. 1999; 9(10):505-11. DOI: 10.1016/s0960-9822(99)80234-6. View

Lindblom A, Linder S . The metastatic phenotype--prognostic implications. Crit Rev Oncol Hematol. 1996; 24(2):71-96. DOI: 10.1016/1040-8428(96)00213-2. View

de StGroth S, Scheidegger D . Production of monoclonal antibodies: strategy and tactics. J Immunol Methods. 1980; 35(1-2):1-21. DOI: 10.1016/0022-1759(80)90146-5. View

Galaktionov K, Lee A, Eckstein J, Draetta G, Meckler J, Loda M . CDC25 phosphatases as potential human oncogenes. Science. 1995; 269(5230):1575-7. DOI: 10.1126/science.7667636. View

Ponniah S, Wang D, Lim K, Pallen C . Targeted disruption of the tyrosine phosphatase PTPalpha leads to constitutive downregulation of the kinases Src and Fyn. Curr Biol. 1999; 9(10):535-8. DOI: 10.1016/s0960-9822(99)80238-3. View

Johnson K, Hill D, Bruskin A . Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Cancer Res. 1992; 52(2):478-82. View

Di Cristofano A, Pandolfi P . The multiple roles of PTEN in tumor suppression. Cell. 2000; 100(4):387-90. DOI: 10.1016/s0092-8674(00)80674-1. View

Hunter T . Signaling--2000 and beyond. Cell. 2000; 100(1):113-27. DOI: 10.1016/s0092-8674(00)81688-8. View

10.

Zheng X, Wang Y, Pallen C . Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature. 1992; 359(6393):336-9. DOI: 10.1038/359336a0. View

11.

Saha S, Bardelli A, Buckhaults P, Velculescu V, Rago C, St Croix B . A phosphatase associated with metastasis of colorectal cancer. Science. 2001; 294(5545):1343-6. DOI: 10.1126/science.1065817. View

12.

Tan Y . Yin and yang of phosphorylation in cytokine signaling. Science. 1993; 262(5132):376-7. DOI: 10.1126/science.7692598. View

13.

Zeng Q, Dong J, Guo K, Li J, Tan H, Koh V . PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 2003; 63(11):2716-22. View

14.

Neel B, Tonks N . Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol. 1997; 9(2):193-204. DOI: 10.1016/s0955-0674(97)80063-4. View

15.

Zeng Q, Hong W, Tan Y . Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun. 1998; 244(2):421-7. DOI: 10.1006/bbrc.1998.8291. View

16.

Cangi M, Cukor B, Soung P, Signoretti S, Moreira Jr G, Ranashinge M . Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000; 106(6):753-61. PMC: 381390. DOI: 10.1172/JCI9174. View